This revised proposal describes a 5 year mentored research project designed to transition the applicant into an independent translational scientist. During the project period, the Principal Investigator (P.l.) will devote efforts towards broadening his knowledge base and technical skills as necessary to ultimately supervise a successful laboratory based program in cancer biology. The development of the P.l. will be fostered by ongoing mentorship by an established expert in the field of cancer biology, Dr. Neal Rosen, at an institution renowned for training clinician scientists in cancer research. Memorial Sloan-Kettering Cancer Center. The focus of the applicant's research is the study of the functions of activated PI3K-AKT signaling in breast cancer. This pathway is activated in many breast cancers including those characterized by HER2 amplification. HER2/ErbB2 primarily activates the PI3K-AKT pathway by dimerizing with the HER3/ErbB3 receptor. The applicant now reports that activation of the PI3K-AKT pathway generates inhibitory signals against the ErbB3 receptor. This proposal is aimed at elucidating the mechanisms and consequences of these inhibitory signals in tumor formation and maintenance. The proposal will test three hypotheses: (1) The PI3K-AKT pathway regulates a discrete set of signals that control the expression of the ErbB3 receptor. (2) The regulation of ErbB3 expression by the PI3K-AKT pathway can impede tumorigenesis but is ultimately overcome in invasive cancers. (3) Therapeutic strategies that incorporate inhibition of ErbB3 induction will be more effective than inhibition of HER2 or AKT alone.
In Aim 1, we will use pharmacologic and genetic manipulations to determine both the context and mechanism of PI3K-AKT regulation of ErbB3 expression.
In Aim 2, we will determine the effect of deregulated ErbB3 expression upon tumor formation and evaluate whether this takes place in human tumor samples.
In Aim 3, we will evaluate the efficacy of combined inhibition of AKT and HER1/2 or selective inhibition of ErbB3 in models of HER2 amplified breast cancer. The overall goal of these studies is to detail the full consequences of activated PI3K-AKT signaling in breast cancer and to develop novel strategies that target dysregulated AKT as therapeutic approaches.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Will, Marie; Qin, Alice Can Ran; Toy, Weiyi et al. (2014) Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 4:334-47
Sakr, Rita A; Weigelt, Britta; Chandarlapaty, Sarat et al. (2014) PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res 20:2326-37
Gala, Kinisha; Chandarlapaty, Sarat (2014) Molecular pathways: HER3 targeted therapy. Clin Cancer Res 20:1410-6
Toy, Weiyi; Shen, Yang; Won, Helen et al. (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439-45
Chandarlapaty, Sarat; Sawai, Ayana; Scaltriti, Maurizio et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71
Scaltriti, Maurizio; Eichhorn, Pieter J; Cortes, Javier et al. (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 108:3761-6
Gajria, Devika; Chandarlapaty, Sarat (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11:263-75
Serra, V; Scaltriti, M; Prudkin, L et al. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547-57